70 million aerobic exercise-related genes switched on — without a single step taken. That's what SLU-PP-332 produced in preclinical models, and it's why this compound has moved from a chemistry lab curiosity to one of the most-discussed molecules in metabolic research.
SLU-PP-332 is a small-molecule pan-ERR agonist — a synthetic activator of the estrogen-related receptors (ERRα, ERRβ, ERRγ) — that instructs your mitochondria, skeletal muscle, and cardiac tissue to behave as if you just finished an endurance training session. The metabolic consequences are striking: obese mice on SLU-PP-332 gained 10 times less fat than controls over 28 days and lost approximately 12% of their body weight, all while eating the same food and doing zero additional exercise.
Contents
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule developed at Saint Louis University and Washington University, first reported in a landmark 2023 paper in ACS Chemical Biology (Billon et al., PMC11584170). The compound was designed to activate ERRα — the nuclear receptor most tightly linked to aerobic exercise adaptation — achieving an EC₅₀ of 98 nM at ERRα, with meaningful activity at ERRβ (230 nM) and ERRγ (430 nM) as well.
Direct answer: SLU-PP-332 is a synthetic pan-ERR agonist that activates all three estrogen-related receptor isoforms (α, β, γ) in energy-demanding tissues. By doing so, it mimics the gene expression and metabolic adaptations triggered by aerobic exercise — including increased fatty acid oxidation, mitochondrial biogenesis, and skeletal muscle fiber type switching — in the absence of physical activity.
The ERR System: The Master Switch for Energy

ERRs are constitutively active orphan nuclear receptors. Their transcriptional activity scales with the energy demands of the tissue. ERRs are expressed most heavily in tissues with the highest energy turnover: skeletal muscle, heart, liver, brain, and adipose tissue.
ERRs sit at the top of a transcriptional hierarchy that governs energy metabolism. Their target genes encode proteins in:
- Fatty acid β-oxidation — breaking down stored fat for fuel
- Mitochondrial biogenesis — building new mitochondria
- TCA cycle enzymes — Krebs cycle for ATP production
- Oxidative phosphorylation components — electron transport chain efficiency
- Glucose transporter regulation — insulin sensitivity pathways
How SLU-PP-332 Works at the Molecular Level
When SLU-PP-332 binds to the ligand-binding domain of ERRα, β, and γ, it stabilizes an active conformation that recruits transcriptional coactivators — primarily PGC-1α and PGC-1β, the same coactivators recruited during actual aerobic exercise. PGC-1α is widely considered the “master regulator” of mitochondrial biogenesis, and it works in direct partnership with ERRα to drive the full aerobic exercise transcriptional program.
Repeated dosing over weeks drives structural muscle remodeling. In the Billon 2023 mouse study, chronic SLU-PP-332 administration produced a measurable shift toward type IIa oxidative muscle fibers — the same fiber type shift that distinguishes endurance-trained athletes from sedentary individuals.
What the Research Actually Shows
Study 1: The Original Characterization (Billon et al., 2023)
Demonstrated SLU-PP-332's synthesis, receptor binding pharmacology, and initial in vivo effects. Key findings: skeletal muscle cell lines showed measurable increases in mitochondrial function and cellular respiration rate; mice showed increased type IIa oxidative muscle fiber content and enhanced treadmill exercise endurance; ERRα-null mice saw the endurance benefit abolished — confirming ERRα as the critical isoform.
Study 2: Metabolic Syndrome and Obesity (PMC10801787, 2024)
Diet-induced obese mice and ob/ob mice received SLU-PP-332 at 50 mg/kg twice daily for 28 days. Results:
- Fat mass reduction: Obese mice gained approximately 10× less fat than vehicle-treated animals and lost around 12% of body weight without dietary restriction
- Increased resting energy expenditure even in the absence of movement
- Insulin sensitivity: Improved glucose tolerance in both DIO and ob/ob models
- Plasma lipids: Decreased total cholesterol and triglycerides
- Lean mass: Preserved — no muscle wasting
- Food intake: Unchanged — fat loss without appetite suppression
Study 3: Heart Failure (PMID 37961903, Circulation 2024)
Using a transaortic constriction (TAC) mouse model of heart failure, SLU-PP-332 produced:
- Improved ejection fraction — heart pumping function significantly restored
- Reduced cardiac fibrosis — less scarring of heart tissue
- Increased survival — lower all-cause mortality
- Enhanced fatty acid metabolism and mitochondrial function in cardiac tissue
The cardiac benefit operates primarily through ERRγ, not ERRα — suggesting muscle endurance and cardiac protection effects can, in principle, be separated with isoform-selective compounds.
Metabolic Benefits: Fat, Insulin, and Cholesterol
SLU-PP-332 is not a thermogenic stimulant. It doesn't raise body temperature by activating sympathetic nervous system pathways. Instead, it increases the efficiency and volume of mitochondrial fat combustion in oxidative tissues — a cleaner, more physiological mechanism that mirrors what happens during sustained aerobic training.
As skeletal muscle shifts toward oxidative metabolism and increases fatty acid utilization, intramyocellular fat accumulation decreases. Intramyocellular lipid is a primary driver of insulin resistance in skeletal muscle — one of the core pathological features of type 2 diabetes. By clearing that lipid through oxidation rather than storage, ERR activation improves the insulin signaling cascade downstream.
Cardiac Protection: The Heart Failure Data
The failing heart undergoes a well-characterized metabolic shift: it stops efficiently burning fatty acids (normally 60–70% of cardiac fuel at rest) and reverts to glucose-dependent metabolism. This fuel switch reduces ATP production efficiency and accelerates the energetic collapse of cardiac function. ERRs are the transcriptional regulators responsible for maintaining fatty acid oxidation capacity in the healthy heart. In heart failure, ERR activity declines.
SLU-PP-332 and SLU-PP-915 produced what the Circulation 2024 paper described as a broad restoration of metabolic gene expression in cardiac tissue: ERRγ activation restored fatty acid oxidation and mitochondrial function, ejection fraction improved, cardiac fibrosis was reduced, and survival increased. This is a genuinely novel mechanism for heart failure therapy — no current approved drug class works primarily by restoring ERR-driven fatty acid metabolism in the myocardium.
Safety Profile and Preclinical Considerations
Published rodent studies at standard research concentrations (10–50 mg/kg, IP administration) show: no reported hepatotoxicity or nephrotoxicity, only minor changes in liver enzymes, preserved lean mass, unchanged food intake, no significant hormonal suppression, and no cardiac hypertrophy induction.
Legitimate open questions:
- No human pharmacokinetic data exists. We don't know absorption, distribution, metabolism, or excretion in humans.
- Long-term safety is unstudied. The longest published mouse study was 28 days.
- Pan-ERR agonism has theoretical risks. ERRs regulate cell proliferation in some cancer cell lines.
- Route of administration matters. All published rodent studies used intraperitoneal injection. Oral bioavailability in humans is uncharacterized.
Frequently Asked Questions
What does SLU-PP-332 actually do in the body?
SLU-PP-332 activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), with the highest potency at ERRα (EC₅₀ = 98 nM). It upregulates the gene programs that aerobic exercise normally triggers — fatty acid oxidation enzymes, mitochondrial biogenesis regulators, and oxidative muscle fiber development. The downstream metabolic effects observed in rodents include increased energy expenditure, fat loss, improved insulin sensitivity, enhanced exercise endurance, and cardiac protection.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small organic molecule, not a peptide. It was developed using medicinal chemistry optimization starting from the GSK4716 scaffold.
How does SLU-PP-332 compare to GW501516 (Cardarine) as an exercise mimetic?
GW501516 acts on the PPARδ receptor and produces some overlapping metabolic effects. The critical difference is the safety profile: GW501516 was abandoned in human trials after preclinical studies showed accelerated tumor growth across multiple cancer types in rodents. SLU-PP-332's safety data, while limited, does not carry that carcinogenicity signal in published studies. The mechanisms are distinct (PPARδ vs. pan-ERR) and the safety trajectories are not comparable.
What is the evidence for SLU-PP-332's cardiac benefits?
The cardiac data come from a 2024 study published in Circulation (PMID 37961903) using a transaortic constriction (TAC) mouse model of heart failure. Both SLU-PP-332 and its analog SLU-PP-915 significantly improved ejection fraction, reduced cardiac fibrosis, and increased survival vs vehicle controls, primarily through ERRγ-mediated restoration of fatty acid metabolism in cardiac tissue.
Are there human clinical trials for SLU-PP-332?
As of early 2026, no human clinical trials for SLU-PP-332 have been published or registered. All existing evidence comes from in vitro cell studies and rodent preclinical models. It is available for laboratory research purposes only.
What makes SLU-PP-332 different from previous ERR agonists?
The critical differentiator is ERRα potency. Previous ERR agonists like GSK4716 were active primarily at ERRβ and ERRγ, with weak activity at ERRα — the isoform most directly responsible for aerobic exercise adaptations in skeletal muscle. SLU-PP-332 achieves ERRα EC₅₀ of 98 nM — a breakthrough potency level.
